CBD and Methotrexate

This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.

Plain-language summary

Methotrexate (MTX) is a widely used drug for rheumatoid arthritis, psoriasis, inflammatory bowel disease, and certain cancers. It works by suppressing cell division, but the doses that help are close to the doses that harm the liver, bone marrow, or kidneys ^[1]. Strong evidence

CBD (cannabidiol) is a non-intoxicating cannabinoid sold as a prescription drug (Epidiolex) and as a largely unregulated supplement. When you take CBD, your liver breaks it down using the same enzymes that clear methotrexate from your blood: CYP3A4, CYP2C9, and CYP2C19 ^[2]. CBD also blocks transporters (P-glycoprotein, BCRP) that pump methotrexate out of cells and into bile and urine ^[3]. Strong evidence

The result is that CBD can slow how quickly your body eliminates methotrexate, raising the drug's blood levels. This has been shown in animal models ^[4]. Strong evidence

The combination is not automatically dangerous, but it is not neutral either. Human controlled data is essentially absent. The prudent stance is: disclose CBD use to your rheumatologist or oncologist before starting methotrexate or CBD, expect closer monitoring of your blood work, and do not self-adjust doses.

This is not medical advice. It is a summary of published evidence. All decisions about methotrexate dosing, or whether to use CBD alongside it, belong to you and your prescriber.

What probably works

In this specific pairing, no intervention meets a 'probably works' bar in humans for clinical benefit.

What is well-established is the biological mechanism of the interaction, not a therapeutic advantage:

• CBD inhibits CYP3A4 and CYP2C enzymes in vitro and in humans at therapeutic doses ^[2]. Strong evidence
• CBD inhibits BCRP and P-glycoprotein transporters, which move methotrexate out of cells into bile and urine ^[3]. Strong evidence
• Methotrexate is a known substrate for BCRP; blocking BCRP raises MTX blood and tissue levels in animal models ^[4]. Strong evidence

So the interaction is real. What has not been established in any controlled human trial is that combining CBD with methotrexate produces any therapeutic benefit — for example, better cancer remission, lower RA disease activity, or reduced side effects — beyond methotrexate alone.

What might work

• CBD for methotrexate-related nausea. Cannabinoids have evidence for chemotherapy-induced nausea, but those trials mostly used THC or the synthetic cannabinoid nabilone, not CBD. Methotrexate causes nausea through effects on the GI tract and chemoreceptor trigger zone; whether CBD addresses this mechanism is not tested ^[5]. Weak / limited

• CBD for arthritis pain in patients taking methotrexate. One observational study and several survey-based reports suggest patients report pain relief, but there are no controlled trials of CBD in rheumatoid arthritis, psoriatic arthritis, or any MTX-treated autoimmune condition ^[6]. Weak / limited

• Reduced methotrexate dose because CBD raises levels. This is mechanistically plausible from animal data: if CBD slows MTX clearance, a lower MTX dose might maintain therapeutic effect with lower toxicity risk. However, no human dosing study has tested this strategy. Do not self-adjust your methotrexate dose. Weak / limited

What doesn't work or lacks evidence

• 'CBD protects your liver from methotrexate damage.' This is a popular claim in wellness marketing. Some rodent studies show CBD reduces markers of MTX-induced liver injury ^[7], but CBD itself has caused transaminase (liver enzyme) elevations in humans in the Epidiolex clinical trials ^[8]. Strong evidence Combining two drugs that can each raise liver enzymes, hoping one will 'protect' against the other, is not supported by evidence. Disputed

• 'CBD boosts methotrexate's anticancer effect.' Preclinical cell-line and animal studies show cannabinoids have anti-tumor activity in laboratory conditions, but there is no human trial showing CBD improves remission rates, survival, or disease response in patients with hematologic or solid malignancies treated with methotrexate No data.

• 'CBD is safe because it is natural or non-intoxicating.' CBD has a documented drug-interaction profile recognized by the FDA and EMA ^[8][9]. Strong evidence Marketing claims that natural compounds are automatically safe with prescription drugs are folklore, not pharmacology.

• Using 'indica' or 'sativa' cannabis strains for autoimmune patients on methotrexate. This is strain-name marketing folklore without pharmacological basis No data.

What we don't know

• The magnitude of the CBD–methotrexate interaction at typical supplement doses (10–50 mg/day) versus prescription Epidiolex doses (up to 20 mg/kg/day). Most published interaction data is from higher-dose studies.

• Whether the interaction matters equally across all methotrexate regimens: low-dose weekly methotrexate (7.5–25 mg/week for rheumatoid arthritis) versus high-dose methotrexate (grams/m² in oncology), which has a much tighter therapeutic window.

• Whether full-spectrum hemp products (containing minor cannabinoids, terpenes, and trace THC) interact the same way as pure, isolated CBD.

• Long-term hepatic and renal safety of combined use in patients with pre-existing liver or kidney disease.

• Whether CBD affects methotrexate polyglutamation inside cells — the intracellular conversion that activates methotrexate's mechanism of action.

Comparison with standard supportive care

Standard approaches to methotrexate tolerability have real trial evidence and are the first-line interventions:

• Folic or folinic acid supplementation (1–5 mg daily, or higher doses weekly) reduces methotrexate-related mouth ulcers, nausea, and liver enzyme elevations in rheumatoid arthritis ^[10]. Strong evidence

• Switching to subcutaneous methotrexate or split dosing reduces nausea, improves bioavailability, and is used routinely when oral tolerance is poor ^[11]. Strong evidence

• Antiemetics such as ondansetron or metoclopramide for acute methotrexate nausea — standard of care in oncology.

• Dose titration and laboratory monitoring (complete blood count, liver function tests, creatinine) every 1–3 months — essential for detecting early toxicity.

CBD does not have evidence at this level for any methotrexate-related indication. If your goal is to tolerate methotrexate better, the interventions above are the ones with trial-based support. See Cannabis and Polypharmacy Risks for broader drug-interaction principles.

Risks and practical considerations

Higher-concern scenarios:

• High-dose CBD (>300 mg/day, or prescription-range Epidiolex dosing).
• Oncology-dose methotrexate (much higher plasma levels, narrower margin between benefit and harm).
• Pre-existing liver disease, history of alcohol use, or concurrent hepatotoxic drugs (leflunomide, isoniazid, azole antifungals).
• Impaired renal function — methotrexate is cleared primarily by the kidneys, and delayed clearance is the main driver of methotrexate toxicity.
• Concurrent NSAIDs, proton-pump inhibitors, trimethoprim, or probenecid, which independently raise methotrexate levels.

Signs of methotrexate toxicity to watch for:

Contact your prescriber urgently if you develop:

• Mouth ulcers or sore throat
• Unusual bruising or bleeding
• Persistent nausea or vomiting
• Dark urine or pale stools
• Yellowing of skin or eyes (jaundice)
• Dry cough or shortness of breath
• Fever or chills
• A drop in your blood counts (reported on lab results)

These require urgent evaluation regardless of CBD use.

Practical steps if you use both:

1. Tell your prescriber (rheumatologist, oncologist, or primary care doctor) the CBD product, dose in milligrams, and frequency. Bring the product label.
2. Avoid starting CBD in the same month you start or dose-escalate methotrexate — you won't know which drug caused a lab abnormality.
3. Prefer CBD products with a third-party certificate of analysis (COA). Unregulated CBD supplements show large discrepancies between labeled and actual cannabinoid content ^[12]. Strong evidence
4. Do not self-adjust your methotrexate dose based on the assumption that CBD has raised your levels. Dose adjustments require blood-work data and clinical judgment.

This is not medical advice. Talk to the clinician who prescribed your methotrexate before starting, stopping, or changing your CBD use.

Sources

How this page was made

Related

• Cannabis and Arthritis Pain — Cannabis may help arthritis pain and sleep, but doesn't replace disease-modifying drugs fo...
• Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.